Version 1
: Received: 16 August 2021 / Approved: 18 August 2021 / Online: 18 August 2021 (14:21:46 CEST)
How to cite:
Quazi, S. Elucidation of CRISPR-Cas9 Application in Novel Cellular Immunotherapy.. Preprints2021, 2021080387. https://doi.org/10.20944/preprints202108.0387.v1
Quazi, S. Elucidation of CRISPR-Cas9 Application in Novel Cellular Immunotherapy.. Preprints 2021, 2021080387. https://doi.org/10.20944/preprints202108.0387.v1
Quazi, S. Elucidation of CRISPR-Cas9 Application in Novel Cellular Immunotherapy.. Preprints2021, 2021080387. https://doi.org/10.20944/preprints202108.0387.v1
APA Style
Quazi, S. (2021). Elucidation of CRISPR-Cas9 Application in Novel Cellular Immunotherapy.. Preprints. https://doi.org/10.20944/preprints202108.0387.v1
Chicago/Turabian Style
Quazi, S. 2021 "Elucidation of CRISPR-Cas9 Application in Novel Cellular Immunotherapy." Preprints. https://doi.org/10.20944/preprints202108.0387.v1
Abstract
Novel Cellular Immunotherapy with engineered T cells has improved cancer treatment and established therapeutic promises to prevent tumor formation in clinical studies. Due to certain restrictions and difficulties, CAR and TCR T cells therapies were inadequate at points. CRISPR Cas9 genome-editing tool has a significant potential for these two cell-based therapies. As a specialized gene-editing technique, CRISPR Cas9 is used to repair genetic alternation with minimum damage. It is used as an adjunct to Immunotherapy to stimulate a more robust immune response. CRISPR has long outpaced other target-specific genome editing methods such as ZFNs and TALEN due to its high efficiency, competence in targeting, and stable operating condition. CRISPR can overcome the two major drawbacks of universal CAR T cells: allorejection and graft-vs-host disease. TCR-based T cell treatment can reduce inappropriate binding between endogenous and transgenic TCR, resulting in a reduction of severe toxicity. The CAR and TCR T based cell therapies uphold an excellent future for tumor malignancies
This article has elucidated the administration of CRISPR Cas9 in Novel Cellular Immunotherapy, CAR, and TCR T cell therapy. However, this article did not fail to observe this technology's ethical concerns, limitations, and challenges. Furthermore, the article compares CRISPR-mediated allogeneic CAR T cell to TCR-T cell therapy.
Keywords
CART CELL, ZFNs, TALEN, TCR T-CELL, CRISPR Cas9
Subject
Biology and Life Sciences, Biology and Biotechnology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
